TAG:
dermatopathology
AmeriPath Will Acquire Specialty Laboratories
By Robert Michel | From the Volume XII No. 14 – October 3, 2005 Issue
CEO SUMMARY: It’s a surprise to most lab industry observers. AmeriPath, a company built around 400 anatomic pathologists working mostly in community hospitals, is acquiring a national reference/esoteric testing company. However, this deal may be better understood by looking at the motiv…
Pinkus DermPath Earns ISO-9000 Certification
By Robert Michel | From the Volume XII No. 11 – August 1, 2005 Issue
CEO SUMMARY: After learning about quality management systems at a recent Executive War College, the lab director at Pinkus Dermatopathology recognized how such techniques could be used in his lab to improve quality, reduce errors, and create a better working environment for both pathologi…
Market Demand for Pathologists Shifts Toward Specialization
By Robert Michel | From the Volume X No. 15 – November 10, 2003 Issue
CEO SUMMARY: Unlike the slack employment market for pathologists seen during the 1990s, there is strong demand for pathologists in this decade. Private pathology group practices now face competition for the best pathology talent. That’s because public lab companies are regularly in the …
Ken Freeman Discusses Plans to Integrate AML and Unilab
By Robert Michel | From the Volume IX No. 6 – April 22, 2002 Issue
CEO SUMMARY: Once again, Ken Freeman and Quest Diagnostics Incorporated is altering the national market for clinical laboratory testing. By acquiring American Medical Laboratories and Unilab, the nation’s largest lab company is expanding its presence in California, Nevada, and Washingto…
“January 7, 2002 Intelligence: Late Breaking Lab News”
By Robert Michel | From the Volume IX No. 1 – January 7, 2002 Issue
Here’s an early conjunction of: 1) consumer demand for sophisticated healthcare services; 2) healthcare ecommerce, and 3) telemedicine. In Cleveland and Boston, major health systems have introduced a Web-based “second opinions” service. In the case of the Cleveland Clinic Foundation…
Analysis of Lab Testing Market Reveals Competitive Shifts
CEO SUMMARY: Even as public lab and anatomic pathology companies enjoy sustained growth in specimen volumes and revenues, fundamental shifts in the basic marketplace have changed the competitive environment. Surprisingly, the most open market segment is anatomic pathology specimens referr…
AmeriPath & InformDX Merging To Form Largest Anatomic Pathology Firm in U.S.
By Robert Michel | From the Volume VII No. 16 – November 13, 2000 Issue
CEO SUMMARY: AmeriPath and InformDX shared several common elements in their respective business strategies. Both companies believe that pathology services are best delivered at the local level and benefit from the support of a national organization. Both companies believe that physicians …
AmeriPath Pursues Ambitious Strategy Of Rapid Expansion
By Robert Michel | From the Volume VII No. 4 – March 6, 2000 Issue
CEO SUMMARY: As the pathology profession’s only publicly-traded physician practice management company, AmeriPath is the spear point of far-reaching changes now transforming pathology. With an annual revenue run rate of $270 million and an ample war chest of growth capital, AmeriPath int…
Pathology Profession Facing New Directions
By Robert Michel | From the Volume VII No. 2 – January 24, 2000 Issue
CEO SUMMARY: Big changes ahead during the next decade. Among the predictions: the number of two and three-pathologist group practices will radically diminish; pathology centers of excellence will achieve new market dominance; and…ever more intense competition for anatomic pathology spec…
Individual Pathologist “Branding” Promoted by National Firms
By Robert Michel | From the Volume VII No. 1 – January 3, 2000 Issue
IN THE EFFORT TO GAIN COMPETITIVE market advantage, IMPATH, Inc. of New York City publicized the recent signing of an exclusive partnership agreement involving renowned pathologist Juan Rosai, M.D., also of New York City. Dr. Rosai has a world-wide reputation for his books, book cha…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized